| 產(chǎn)品編號 | bs-12393R-Gold |
| 英文名稱1 | Rabbit Anti-BCL9/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的B淋巴細(xì)胞淋巴瘤因子9抗體 |
| 別 名 | B-cell CLL/lymphoma 9; BCL 9; BCL-9; DLNB11; Legless homolog; B-cell CLL/lymphoma 9-like; LGS; BCL9_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 染色質(zhì)和核信號 轉(zhuǎn)錄調(diào)節(jié)因子 淋巴細(xì)胞 b-淋巴細(xì)胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 149kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BCL9 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: Bcl-9L is a 1,499 amino acid protein that localizes to the nucleus and contains a specialized C-terminal domain that is important for its overall activity. Expressed in breast tissue, as well as in eye, lung, prostate and various carcinomas, Bcl-9L functions as a transcriptional activator that forms a complex with Parafibromin and β-catenin and is thought promote the transcriptional activity of Parafibromin and enhance the neoplastic transforming activity of β-catenin. Bcl-9L exists as multiple alternatively spliced isoforms and is thought to be involved in tumorigenesis, possibly playing a role in tumor transformation and metastasis. The gene encoding Bcl-9L maps to human chromosome 11, which houses over 1,400 genes and comprises nearly 4% of the human genome. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are associated with defects in genes that maps to chromosome 11. Function: BCL9 is involved in signal transduction through the Wnt pathway. It promotes beta-catenin's transcriptional activity. BCL9 is associated with B-cell acute lymphoblastic leukemia. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies (referenced from swissprot and entrez gene). Subunit: Binds to beta-catenin (CTNNB1), PYGO1 and PYGO2. Subcellular Location: Nuclear Tissue Specificity: Detected at low levels in thymus, prostate, testis, ovary and small intestine, and at lower levels in spleen, colon and blood. Post-translational modifications: Phosphorylated upon DNA damage, probably by ATM or ATR. DISEASE: Note=A chromosomal aberration involving BCL9 is found in a patient with precusor B-cell acute lymphoblastic leukemia (ALL). Translocation t(1;14)(q21;q32). This translocation leaves the coding region intact, but may have pathogenic effects due to alterations in the expression level of BCL9. Several cases of translocations within the 3'-UTR of BCL9 have been found in B-cell malignancies. Similarity: Belongs to the BCL9 family. Database links: UniProtKB/Swiss-Prot: O00512.4 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
